Follicular Lymphoma Excellence Forum

Follicular Lymphoma

Excellence Forum

Leaders in the field sharing authoritative insights and institutional best practices.

Craig Portell, MD, University of Virginia Health

Videos

Frontline Venetoclax Plus Obinutuzimab and Bendamustine for Patients With High Tumor Burden FL

03/23/2022

Craig A Portell, MD, talks about a phase 2 study of venetoclax in combination with obinutuzumab and bendamustine for patients with high tumor burden FL as frontline therapy.

Craig A Portell, MD, talks about...

03/23/2022

Oncology

Podcasts

Tazemetostat Plus Lenalidomide and Rituximab for Relapsed/Refractory FL: Promising Data From SYMPHONY-1 Trial

03/21/2022

Connie Batlevi, MD, PhD, shares updated safety and efficacy data from the SYMPHONY-1 trial of tazemetostat, a first-class oral selective EZH2 inhibitor, for patients with FL.

Connie Batlevi, MD, PhD, shares...

03/21/2022

Oncology

Elizabeth Brem, MD, Chao Family Comprehensive Cancer Center, University of California Irvine

Videos

Current Treatment Landscape, Emerging Therapies for Patients With FL

03/04/2022

Elizabeth Brem, MD, discusses the current treatment landscape and new emerging therapies, such as CAR-T, for FL.

Elizabeth Brem, MD,...

03/04/2022

Oncology

Videos

Dr Strati Highlights Lenalidomide Plus Rituximab for FL

02/15/2022

Paolo Strati, MD, highlights long-term follow-up results of lenalidomide and rituximab as initial treatment for patients with FL.

Paolo Strati, MD, highlights...

02/15/2022

Oncology

Videos

Dr McKinney on the Efficacy, Safety of Parsaclisib for R/R FL

02/15/2022

Matthew McKinney, MD, overviews the phase 2 CITADEL-203 study on parsaclisib in patients with R/R FL, presented at ASH 2021.

Matthew McKinney, MD, overviews...

02/15/2022

Oncology

Videos

Dr Ghosh Overviews Glofitamab Plus R-CHOP for R/R NHL, Including FL, DLBCL

01/13/2022

Nilanjan Ghosh, MD, highlights preliminary results from a dose-escalation and safety run-in phase 1b study of glofitamab plus R-CHOP for patients with R/R NHL and previously untreated DLBCL, presented at ASH 2021.

Nilanjan Ghosh, MD, highlights...

01/13/2022

Oncology

Videos

Dr Mehta-Shah Discusses the Treatment Paradigms for T-Cell Lymphomas

01/07/2022

Neha Mehta-Shah, MD, MSCI, discusses various treatment paradigms for T-cell lymphomas, including primary cutaneous T-cell lymphomas and peripheral T-cell lymphomas.

Neha Mehta-Shah, MD, MSCI,...

01/07/2022

Oncology

Videos

John Leonard, MD, Discusses the Lymphoma Treatment Landscape

11/04/2021

Dr Leonard discusses the complex landscape and management of patients with lymphoma, including the use of monsunetuzumab therapy.

Dr Leonard discusses the complex...

11/04/2021

Oncology

Videos

Researchers Discuss Combo Therapy for B-Cell Lymphomas

06/02/2021

Alex Herrera, MD, and Amitkumar Mehta, MD, discuss the safety and activity of ibrutinib in combination with durvalumab for B-cell lymphomas.

Alex Herrera, MD, and Amitkumar...

06/02/2021

Oncology

Videos

Dr Hutchings Discusses Glofitamab for R/R B-Cell Lymphoma

04/20/2021

Dr Martin Hutchings discusses his study on glofitamab, a bispecific antibody, in relapsed or refractory B-cell NHL.

Dr Martin Hutchings discusses...

04/20/2021

Oncology

Recent News

Commentary

Challenges of Managing FL: A Focus on PI3K Inhibitors and Next-Line Therapy

04/26/2020

Elizabeth Brem, MD, discusses some of the challenges with managing FL, focusing on the incorporation of PIK3 kinase inhibitors in the treatment of these patients.

Elizabeth Brem, MD, discusses...

04/26/2020

Oncology

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology